de Genève, (Genève, Switzerland), Uppsala University Hospital (Uppsala, Sweden) and the Centre Hospitalier Regional Universitaire de Lille (France). The programme is coordinated by the San Raffaele Diabetes Research Institute and receives financial support from the JDRF. A web-based platform was developed in 2009 to coordinate and track programme activity (http://ecit.dri-sanraffaele.org/en/register/ index.html). Islet isolation and shipment were performed according to centre protocols. Here we report on programme activity over the past 5 years (from 1 November 2009 to 31 October 2014).
One-hundred and twenty research groups have completed the online registration process. Of these, 66 users have made at least one application to receive islets. A total of 93 applications were submitted from 13 countries: Switzerland (n=26), Sweden (n=13), Israel (n=13), Germany (n=12), France (n=9), Italy (n=7), Spain (n=4), Denmark (n=3), UK (n=2) and one each from Austria, Norway, Ireland and Finland. The total number of islets requested was 106.187 million (Fig. 1a ). An ideal islet purity of ≥70% was requested in 97% of the applications. In terms of applications from individual research groups, the median number of requested islets was 20×10 Over the first 5 years of the programme, a total of 31.643 million human islets have been distributed throughout 1,130 shipments (Fig 1a,b) . The production and delivery of islets by the ECIT centres have been stable over the years. However, because of the burgeoning demand for islets and the lack of funding to cover additional islet isolation procedures, the ECIT centres went from supplying 74% of the requested islets in 2010 to only 20% in 2014. Users were requested to give feedback on perceived islet quality by filling a specific form. The mean perceived quality feedback scored 1.81±0.7 on a scale of 1-4 (where 1=excellent, 2=good, 3=fair, 4=bad) overall. The values for specific centres were Milan 1.79± 0.79, Geneva 1.76 ± 0.77, Lille 1.88 ± 0.73 and Uppsala 1.86±0.51. Ninety per cent of the islets processed and distributed by ECIT were ranked as excellent or good in quality by the researchers who received them.
A total of 65 academic investigators representing 40 institutions received human islets for 80 approved studies. These studies have so far resulted in 111 publications directly attributable to the use of human islets supplied by ECIT laboratories, with a total impact factor (IF) of 807.212 (average IF per item, 7.27). An Institute for Scientific Information Web of Knowledge search (November 2014) yielded the following information on 107 of these publications: articles appeared in more than 39 journals, with a median impact factor of 4.648, and were cited 1,833 times from 2009 to 2014 (average citations per item, 17.13; average citations per year, 305.5; citations in the last year, 555; h-index, 22).
Research activity related to beta cell biology has drastically increased over recent years, leading to a significant rise in the demand for human pancreatic islets [1, 3] . This is because human pancreatic islets are still the gold standard for the assessment of beta cell function, even though a variety of surrogate alternatives have been suggested, including non-human pancreatic islets or rodent/human beta cell lines [4] [5] [6] [7] . Even though molecular, cellular and genetic data have been collected from these surrogate models and have proved useful for certain aspects of beta cell maturation and function, many studies have shown species-specific differences in islets (especially between human and rodent models) and line-specific differences in islet-like insulinproducing cells obtained from germ-cell precursors when examining proliferative potential, differentiation capacity, response to injury, composition and organisation of cell clusters, and type and amount of secreted products. Based on the experience of the human islet distribution programme for basic research in Europe and of similar islet distribution programmes, it has become evident that sufficient supply and further I r e l a n d F i n l a n d stimulation of translational research is critically dependent on an enhanced availability of high-quality and high-purity human islet preparations [3, 8] . The 5 year analysis of our activity highlights one critical issue: the expanding gap between the demand for islets and the supply available. Although the programme has so far succeeded in meeting at least a small proportion of the islet demand, it is very likely that in the next few years this will not be the case. The situation may be about to worsen for two reasons. The sustained improvement in the isolation procedure, combined with the progressive increase of isolation costs, will reduce the proportion of preparations unsuitable for the clinic, further restricting the availability of islets for research. Moreover, the European Commission will soon award the first grants of the Horizon 2020 programme 'Biomaterial for the treatment of diabetes mellitus' (http://ec.europa.eu/ research/participants/portal/desktop/en/opportunities/ h2020/topics/2511-nmp-10-2014.html), and this funding will generate a dramatic increase in human islet d e m a n d . T h e E C I T h u m a n i s l e t d i s t r i b u t i o n programme for basic research was established to help address the supply and demand issues faced by islet isolation laboratories and basic scientists. Over the first 5 years of the programme, islets have been provided free of charge. Although this distribution network has had a global influence on diabetes research, in the future it will likely face economic hurdles to providing human islets to a growing research community.
